

RESTRATA® Benefit and Response During COVID-19 **Differentiating Restrata from Other Wound Treatments**

A Non-biologic is the Preferred Option

The benefit of a non-biologic resonates even more during the COVID-19 crisis. Non-biologics can be clearly differentiated in terms of non-risk to the patient and the facility in comparison to skin substitutes or Human Cellular Tissue products (HCT/P) that can pose a risk to patients and facilities due to the biologic component inherent in these products. Many require special handling and licensure by each State that is no doubt being challenged during the pandemic. This was previously borne out with the Zika virus where hospital personnel questioned the potential risk in utilizing HCT/P products.

Benefits of Restrata

- Restrata is a non-biologic, synthetic matrix that is terminally sterilized and presents no risk of disease or viral transmission¹ in contrast to HCT/Ps or other skin substitutes.
- Restrata is wholly manufactured in the USA and Acera's supply chain is not at risk of interruption due to disease or foreign threats. Restrata's manufacturing capabilities risk no interruption as harvesting of human or animal tissues is not required.
- Some human amniotic suppliers are finding restricted access to labor and delivery units at hospitals when procuring placentas for HCT/P processing due to the COVID-19 risk of transmission and limited access to hospital patients.
- Restrata does not require weekly re-application; it persists in the wound for weeks, reducing the number of clinic visits for patients translating to less risk of exposure to COVID or other viruses.
- Emergent wound cases requiring surgical intervention may be reduced with the positive healing outcomes demonstrated with Restrata.
- Restrata time-to-healing may reduce inpatient cases freeing hospital beds for COVID-19 cases.
- Restrata ease-of-use does not require extensive monitoring as it is NOT a dressing and is NOT removed¹.
- Restrata provides a cost benefit to Medicare due to the need for fewer applications throughout the wound healing process. The facility can save monies with less product purchases required.
- Restrata does not require special storage or handling and can be transported, stored, and utilized in alternative health care sites of service¹.
- Restrata's two-year shelf life is advantageous for hospitals/clinics that want to stock-up product to reduce contact with vendors contracts minimizing frequent deliveries.
- Religious and ethnic concerns do not exist with Restrata as with HCT/P products from human origin, as Restrata is a non-biologic, non-human, and non-animal product. This may eliminate concerns and religious objections of patients who are Native American, Muslim or Jehovah's Witness.

¹MKG-20002 Restrata IFU. Please refer to the Restrata package insert for approved indications and instructions for use.

²MacEwan MR, MacEwan S, Kovacs TR, et al. (October 2, 2017) What Makes the Optimal Wound Healing Material? A Review of Current Science and Introduction of a Synthetic Nanofabricated Wound Care Scaffold. Cureus Journal of Medical Science 9(10): e1736. doi:10.7759/cureus.1736